, Central Brain Tumor Registry of the United States, 2012.

V. Rigau, S. Zouaoui, H. Mathieu-daudé, A. Darlix, and A. Maran, French brain tumor database: 5-year histological results on 25 756 cases, Brain Pathol, vol.21, pp.633-644, 2011.
DOI : 10.1111/j.1750-3639.2011.00491.x

D. N. Louis, H. Ohgaki, O. D. Wiestler, W. K. Cavenee, and P. C. Burger, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, vol.114, pp.97-109, 2007.

G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, and B. Scheithauer, Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402, J Clin Oncol, vol.24, pp.2707-2714, 2006.

M. J. Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, and M. Taphoorn, Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial, J Clin Oncol, vol.24, pp.2715-2722, 2006.

J. Reifenberger, G. Reifenberger, L. Liu, C. D. James, and W. Wechsler, Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p, Am J Pathol, vol.145, pp.1175-1190, 1994.

J. G. Cairncross, K. Ueki, M. C. Zlatescu, D. K. Lisle, and D. M. Finkelstein, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst, vol.90, pp.1473-1479, 1998.

R. B. Jenkins, H. Blair, K. V. Ballman, C. Giannini, and R. M. Arusell, A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res, vol.66, pp.9852-9861, 2006.

C. A. Griffin, P. Burger, L. Morsberger, R. Yonescu, and S. Swierczynski, Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss, J Neuropathol Exp Neurol, vol.65, pp.988-994, 2006.

H. Yan, D. W. Parsons, J. G. Mclendon, R. Rasheed, and B. A. , IDH1 and IDH2 mutations in gliomas, N Engl J Med, vol.360, pp.765-773, 2009.

M. Sanson, Y. Marie, S. Paris, A. Idbaih, and J. Laffaire, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J Clin Oncol, vol.27, pp.4150-4154, 2009.

A. Idbaih, E. Crinière, Y. Marie, A. Rousseau, and K. Mokhtari, Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas, Neuro-oncology, vol.10, pp.540-547, 2008.
DOI : 10.1215/15228517-2008-022
URL : https://hal.archives-ouvertes.fr/inserm-00310501

C. Bettegowda, N. Agrawal, Y. Jiao, M. Sausen, and L. D. Wood, Mutations in CIC and FUBP1 contribute to human oligodendroglioma, Science, vol.333, pp.1453-1455, 2011.
DOI : 10.1126/science.1210557

F. Sahm, C. Koelsche, J. Meyer, S. Pusch, and K. Lindenberg, CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas, Acta Neuropathol, vol.123, pp.853-860, 2012.
DOI : 10.1007/s00401-012-0993-5

S. Yip, Y. S. Butterfield, O. Morozova, S. Chittaranjan, and M. D. Blough, Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers, J Pathol, vol.226, pp.7-16, 2012.
DOI : 10.1002/path.2995
URL : http://europepmc.org/articles/pmc3246739?pdf=render

. Home-clinicaltrials, , 2012.

C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, and R. Guillevin, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in lo w-grade g li oma s, Neurolo gy, vol.75, pp.1560-156, 2010.

M. E. Ritchie, B. S. Carvalho, K. N. Hetrick, S. Tavaré, and R. A. Irizarry, / Bioconductor software for Illumina's Infinium whole-genome genotyping BeadChips, Bioinformatics, vol.25, pp.2621-2623, 2009.
DOI : 10.1093/bioinformatics/btp470
URL : https://academic.oup.com/bioinformatics/article-pdf/25/19/2621/439195/btp470.pdf

R. B. Scharpf, I. Ruczinski, B. Carvalho, B. Doan, and A. Chakravarti, A multilevel model to address batch effects in copy number estimation using SNP arrays, Biostatistics, vol.12, pp.33-50, 2011.
DOI : 10.1093/biostatistics/kxq043
URL : https://academic.oup.com/biostatistics/article-pdf/12/1/33/18606402/kxq043.pdf

H. Bengtsson, P. Neuvial, and T. P. Speed, TumorBoost: normalization of allelespecific tumor copy numbers from a single pair of tumor-normal genotyping microarrays, BMC Bioinformatics, vol.11, p.245, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01199777

W. Sun, F. A. Wright, Z. Tang, S. H. Nordgard, V. Loo et al., Integrated study of copy number states and genotype calls using high-density SNP arrays, Nucleic Acids Res, vol.37, pp.5365-5377, 2009.
DOI : 10.1093/nar/gkp493
URL : https://academic.oup.com/nar/article-pdf/37/16/5365/16753349/gkp493.pdf

Y. Benjamini, D. Drai, G. Elmer, N. Kafkafi, and I. Golani, Controlling the false discovery rate in behavior genetics research, Behav Brain Res, vol.125, pp.279-284, 2001.
DOI : 10.1016/s0166-4328(01)00297-2
URL : http://homepages.gold.ac.uk/aphome/benjamini_fdr.pdf

M. Labussière, A. Idbaih, X. Wang, Y. Marie, and B. Boisselier, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, vol.74, pp.1886-1890, 2010.

B. C. Christensen, A. A. Smith, S. Zheng, D. C. Koestler, and E. A. Houseman, DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma, J Natl Cancer Inst, vol.103, pp.143-153, 2011.
DOI : 10.1093/jnci/djq497
URL : https://academic.oup.com/jnci/article-pdf/103/2/143/17311259/djq497.pdf

W. Xu, H. Yang, Y. Liu, Y. Yang, and P. Wang, Oncometabolite 2hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases, Cancer Cell, vol.19, pp.17-30, 2011.
DOI : 10.1016/j.ccr.2010.12.014
URL : https://doi.org/10.1016/j.ccr.2010.12.014

S. Turcan, D. Rohle, A. Goenka, L. A. Walsh, and F. Fang, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, vol.483, pp.479-483, 2012.

M. J. Van-den-bent, L. A. Gravendeel, T. Gorlia, J. M. Kros, and L. Lapre, A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951, Clin Cancer Res, vol.17, pp.7148-7155, 2011.

H. Makishima and J. P. Maciejewski, Pathogenesis and consequences of uniparental disomy in cancer, Clin Cancer Res, vol.17, pp.3913-3923, 2011.
DOI : 10.1158/1078-0432.ccr-10-2900
URL : http://clincancerres.aacrjournals.org/content/17/12/3913.full.pdf

A. Idbaih, Y. Marie, G. Pierron, C. Brennetot, and K. Hoang-xuan, Two types of chromosome 1p losses with opposite significance in gliomas, Ann Neurol, vol.58, pp.483-487, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00310519

J. Jeuken, S. Cornelissen, S. Boots-sprenger, S. Gijsen, and P. Wesseling, Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors, J Mol Diagn, vol.8, pp.433-443, 2006.

M. Benetkiewicz, A. Idbaih, P. Cousin, B. Boisselier, and Y. Marie, NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas, PLoS ONE, vol.4, p.4107, 2009.
DOI : 10.1371/journal.pone.0004107
URL : https://doi.org/10.1371/journal.pone.0004107